MDX Medx Health Corp

MedX Survey Confirms Almost 90% of Moles Biopsied Are Benign MISSISSAUGA, ON, May 16, 2012 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy and light imaging systems, announced the results of a recent MedX survey launched via a press release on April 12, 2012 and concluded in May, which has been designated as Melanoma/Skin Cancer Prevention Month by the American Academy of Dermatology.  The results over the last month confirm earlier studies that show that most moles (90%) that are biopsied are benign and did not need to be removed. Alternative approaches are therefore required to increase the precision of assessment of pigmented skin lesions. MoleMate uses light waves to create images that allow physicians to see below the mole, under the skin, and determine if a mole is malignant, within seconds, without surgery, resulting in a sharp reduction of the moles removed, or biopsied.  MoleMate allows an "optical biopsy" and reduces the pain and stress for patients and reduces the cost of care to the medical system. MedX says that with 14 million Americans living with a history of melanoma and non-melanoma skin cancer, this technology is designed with the welfare of patients in mind, and that according to the Canadian and US Cancer Societies, when melanoma is detected early, the survival rate is about 99 per cent. "MoleMate allows physicians and patients to know immediately what a time consuming and painful biopsy would have revealed," said Steve Guillen, President & CEO, and "fewer surgical biopsies save the health care system money, and improve the quality of care of patients with suspicious moles." About MoleMate Imaging and Skin Cancer MoleMate recently received approval from Health Canada, and is immediately available and in stock for all Canadian physicians, joining their colleagues in Europe, the UK, Australia, and the US, who have been utilizing this new pain-free, non-invasive imaging system to 'See More', approximately 2mm below the surface of suspicious moles, and provide additional information and images related to every mole and all types of melanomas and non-melanomas. MoleMate uses a patented device and technology that features a hand-held scanner designed for office use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images for physicians to evaluate all types of moles and lesions within seconds, providing images that can reveal if a mole is benign, or something more serious, often eliminating the need for skin biopsies, resulting in less pain, scarring, and expense.  Physicians interested in learning more should contact MedX Health Corp. at www.simsys-molemate.com. "Among the sophisticated equipment used by University of California Irvine Melanoma Center physicians is a SIMSYS-MoleMate SIAscope, one of the most advanced melanoma imaging systems in the world. For patients with many moles, this computer imaging can make a big difference, it decreases the number of biopsies needed, so they won't look like a pincushion." - Dr. James G. Jakowatz, surgical oncologist and UC Irvine Melanoma Center director - Dr. Janellen Smith, UC Irvine dermatologist and co-director of the Pigmented Lesion Program, UC Irvine MoleMate and the more robust system, SIMSYS, are both sold with a specially designed training CD.  SIMSYS allows image capture and storage as well as special features that can be used in visualizing and comparing moles.  SIMSYS will include "mole mapping" software in 2012.  Mole Mapping is a technique that physicians use on certain patients with 50-100 or more moles where the entire surface of the patient's skin is photographed to observe changes over time and then suspicious moles can be monitored more closely or, if necessary, removed. MoleMate is easy to incorporate into exams, and is easy for physicians to learn how to use via the 60-90 minute training CD, as documented in a study with general practitioners, who significantly improved their ability to more accurately identify suspicious moles and lesion. Recent competitive product entries are more costly to acquire and use, and do not offer the range of feedback on all moles that is possible with MoleMate, including the ability to store and make side-by-side comparisons of images to track changes, which are advantages of the MoleMate system and will continue to differentiate the MedX products in this new emerging market. Learn More The website www.simsys-molemate.com contains additional information on MoleMate and SIMSYS, including information on the technology behind these products, as well as product demos, and information on how other physicians have integrated the skin cancer imaging system into their practice. Skin Cancer - The Most Common Form of Cancer The Canadian and US Cancer societies confirm that skin cancer is the most common form of cancer.  Each year there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostrate, lung and colon. Nearly 800,000 Americans are living with a history of melanoma and 13 million Americans are living with a history of non-melanoma skin cancer, typically diagnosed as basal cell carcinoma (BCC) or squamous cell carcinoma (SCC).  When melanoma is detected early, the survival rate is about 99% and falls to 15% as the disease advances. Corporate Partners Proctor & Gamble, LenioMed Ltd., and ScreenCancer, Inc., are research and commercial partners that are funding the expansion of the underlying technology, into new consumer and wound care markets. About MedX Health Corp. MedX is a twelve (12) year old Canadian company, headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canada cleared, and CE Mark approved for use in North America as well as the European Union.  MedX Health acquired the worldwide assets of MoleMate in June, 2011.  For a complete profile of MedX Health Corp. and its products visit www.medxhealth.com. This press release does not constitute an offer of any securities for sale.  This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation.  These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements.  All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. MedX Health Corp. CONTACT: Investors:Steve GuillenPresident and Chief Executive OfficerMedX Health Corp. investor@medxhealth.comPhone: (905) 670-4428

Copyright